1. What is Pharmacovigilance?

Pharmacovigilance (PV) is the science and set of activities related to detecting, assessing, understanding, and preventing adverse effects or any other drug-related problems.

It ensures that medicines remain safe after they reach the market, because clinical trials cannot detect all risks (especially rare or long-term effects).

2. Core Duties of Pharmacovigilance

A. Adverse Drug Reaction (ADR) Monitoring

• Collecting reports of side effects from:
  • Doctors
  • Pharmacists
  • Patients
  • Hospitals
• Recording both expected and unexpected reactions

B. Signal Detection

• Identifying new safety risks from accumulated data
• Using statistical tools and databases to find patterns

C. Risk Assessment and Management

• Evaluating seriousness and frequency of ADRs
• Deciding:
  • Warning updates
  • Dose changes
  • Restricted use
  • Withdrawal of drug

D. Regulatory Reporting

• Submitting safety reports to authorities like:
  • FDA (USA)
  • EMA (Europe)
  • CDSCO (India)
• Includes:
  • Individual Case Safety Reports (ICSRs)
  • Periodic Safety Update Reports (PSUR/PBRER)

E. Post-Marketing Surveillance (PMS)

• Monitoring drugs after approval
• Detecting rare or long-term adverse effects not seen in trials

F. Benefit–Risk Evaluation

• Continuously balancing:
  • Therapeutic benefit vs. harm
• Deciding whether drug should remain on market

G. Risk Communication

• Updating:
  • Package inserts
  • Black box warnings
  • Dear healthcare provider letters

H. Patient Safety Programs

• Implementing controlled access systems for high-risk drugs
• Example: pregnancy prevention programs

3. Important Case Laws / Drug Safety Cases (Detailed Explanation)

Case 1: Thalidomide Tragedy (1957–1961)

Background

• Drug: Thalidomide (sedative for morning sickness in pregnancy)
• Marketed in Europe, Canada, and other countries
• Not properly tested for pregnancy safety

What happened?

• Thousands of babies were born with:
  • Phocomelia (short or absent limbs)
  • Ear, heart, and internal organ defects

Pharmacovigilance failure

• No proper teratogenicity testing
• Weak post-marketing surveillance
• Early warning signals ignored

Outcome

• Drug withdrawn worldwide
• Massive regulatory reform:
  • Mandatory clinical trials before approval
  • Pregnancy safety testing
  • Stronger drug monitoring systems

PV lesson

This case is the foundation of modern pharmacovigilance systems.

Case 2: Vioxx (Rofecoxib) – Merck (2004)

Background

• Drug: Rofecoxib (Vioxx), painkiller (NSAID)
• Approved for arthritis and pain

Problem discovered

• Increased risk of:
  • Heart attacks
  • Stroke

What happened?

• Internal studies suggested cardiovascular risk early
• Drug still marketed widely
• Millions of patients exposed

Legal outcome

• Drug withdrawn in 2004
• Thousands of lawsuits against Merck
• Billion-dollar settlements

Pharmacovigilance issue

• Delayed signal detection and reporting
• Allegations of suppressed safety data

PV lesson

• Importance of transparent signal reporting and rapid risk communication

Case 3: Fen-Phen (Fenfluramine + Phentermine) – 1997

Background

• Used as weight-loss combination therapy

Safety issue discovered

• Caused:
  • Heart valve damage
  • Pulmonary hypertension

How detected?

• Post-marketing case reports + echocardiography studies
• FDA received increasing ADR signals

Outcome

• Fenfluramine withdrawn from market
• Large-scale class action lawsuits
• Compensation for affected patients

PV failure point

• Rare but serious cardiac toxicity was not detected in clinical trials

PV lesson

• Need for long-term cardiovascular monitoring after approval

Case 4: Troglitazone (Rezulin) – 2000

Background

• Anti-diabetic drug (Type 2 diabetes treatment)
• Introduced as insulin sensitizer

Safety issue

• Severe liver toxicity (hepatotoxicity)
• Led to liver failure and deaths

Warning signals

• Early case reports of elevated liver enzymes ignored initially
• Delayed regulatory response

Outcome

• Withdrawn from US and global markets in 2000

Legal impact

• Lawsuits against manufacturer (Parke-Davis/Pfizer acquisition era issues)

PV lesson

• Importance of early liver function monitoring and rapid action on toxicity signals

Case 5: Isotretinoin (Accutane) – Birth Defects Litigation

Background

• Drug: Isotretinoin for severe acne
• Highly effective but teratogenic

Problem

• Causes severe birth defects if taken during pregnancy:
  • Brain defects
  • Heart abnormalities
  • Facial malformations

Pharmacovigilance response

• Strict pregnancy prevention systems introduced:
  • Mandatory pregnancy tests
  • Birth control requirements
  • Controlled dispensing programs (e.g., iPLEDGE system in US)

Legal issues

• Multiple lawsuits alleging inadequate warning and counseling

PV lesson

• High-risk drugs require controlled distribution + strict monitoring programs

Case 6: Paroxetine (Paxil) – SSRI Safety Controversy

Background

• Antidepressant (SSRI) used for depression and anxiety

Safety issue

• Linked to:
  • Increased risk of suicidal thoughts in adolescents
  • Withdrawal syndrome
  • Congenital risks in pregnancy

Pharmacovigilance findings

• Post-marketing studies and meta-analyses revealed risks not clear in trials

Legal outcome

• Lawsuits alleging selective data publication and inadequate warnings

PV lesson

• Importance of complete and transparent clinical data reporting

4. Key Takeaways (Pharmacovigilance Duties from Cases)

From all these landmark cases, pharmacovigilance systems evolved to ensure:

• Early detection of rare ADRs
• Mandatory post-marketing surveillance
• Strong regulatory reporting systems
• Transparent communication of risks
• Rapid withdrawal or restriction of unsafe drugs
• Patient protection programs for high-risk medicines